IP Library › Patent Application 13831099
Patent Application
App. No. 13/831,099

ANTIBODIES TO OPGL

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/831,099
Abstract

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

Claims (20)

1 - 29 . (canceled)

30 . An antibody; comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the light chain comprises the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

31 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises the variable region and the constant region of SEQ ID NO:2 having one carboxy-terminal amino acid deletion, and wherein the light chain comprises the variable region and the constant region of SEQ ID NO:4 having one carboxy-terminal amino acid deletion.

32 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises the variable region and the constant region of SEQ ID NO:2 having one carboxy-terminal amino acid deletion; and wherein the light chain comprises the variable region and the constant region of SEQ ID NO:4.

33 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable region comprising the amino acid sequence as forth in SEQ ID NO: 13 and a light chain, wherein the antibody binds to an osteoprotegerin ligand (OPGL).

34 . The antibody of claim 33 , wherein the antibody inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR).

35 . An antibody, comprising a heavy chain and a light chain, wherein the light chain comprises a variable region comprising the amino acid sequence as set forth in SEQ ID NO: 14, and a heavy chain, wherein the antibody binds to an osteoprotegerin ligand (OPGL).

36 . The antibody of claim 35 , wherein the antibody inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR).

37 . A pharmaceutical composition comprising the antibody of any one of claims 30 , 31 , and 32 .

38 . The pharmaceutical composition of claim 37 , wherein the composition comprises an acetate buffer.

39 . The pharmaceutical composition of claim 37 , wherein the composition comprises polysorbate.

40 . The pharmaceutical composition of claim 37 , wherein the composition comprises sorbitol.

41 . The pharmaceutical composition of claim 37 , wherein the composition comprises acetate and sorbitol.

42 . The pharmaceutical composition of claim 37 , wherein the composition is contained in a prefilled syringe.

43 . The pharmaceutical composition of claim 38 , wherein the composition is contained in a prefilled syringe.

44 . The pharmaceutical composition of claim 39 , wherein the composition is contained in a prefilled syringe.

45 . The pharmaceutical composition of claim 40 , wherein the composition is contained in a prefilled syringe.

46 . The pharmaceutical composition of claim 41 , wherein the composition is contained in a prefilled syringe.

47 . The pharmaceutical composition of claim 37 , wherein the composition is in unit dose form.

48 . A pharmaceutical composition comprising the antibody of any one of claims 33 , 34 , 35 , and 36 .